Zhang Le, Ebenezer Philip J, Dasuri Kalavathi, Bruce-Keller Annadora J, Liu Ying, Keller Jeffrey N
Pennington Biomedical Research Center/Louisiana State University System, Baton Rouge, Louisiana 70808-4124, USA.
J Neurosci Res. 2009 Nov 1;87(14):3231-8. doi: 10.1002/jnr.22147.
In this study we examined whether established signal transduction cascades, p44/42 mitogen-activated protein kinase (ERK1/2) and Jun N-terminal kinases (JNK) pathways, are altered in N2a neural cells in response to proteasome inhibition. Additionally, we sought to elucidate the relative contribution of these signal transduction pathways to the multiple downstream effects of proteasome inhibition. Our data indicate that ERK1/2 and JNK are activated in response to proteasome inhibition. Washout of proteasome inhibitor (MG132) results in an enhancement of ERK1/2 activation and amelioration of JNK activation. Treatment with an established MAPK inhibitor resulted in an increase in proteasome inhibitor toxicity, and incubation with JNK inhibitor was observed to attenuate proteasome inhibitor toxicity significantly. Subsequent studies demonstrated that inhibition of ERK1/2 and JNK activity does not alter the gross increase in ubiquitinated protein following proteasome inhibitor administration. Similarly, ERK1/2 and JNK activity do not appear to play a role in the disruption of polysomes following proteasome inhibitor administration in neural cells. Together these data indicate that ERK1/2 and JNK activation may play differential roles in modulating neurochemical disturbances and neurotoxicity induced by proteasome inhibition.
在本研究中,我们检测了已确立的信号转导级联反应,即p44/42丝裂原活化蛋白激酶(ERK1/2)和Jun氨基末端激酶(JNK)通路,在N2a神经细胞中对蛋白酶体抑制的反应是否发生改变。此外,我们试图阐明这些信号转导通路对蛋白酶体抑制的多种下游效应的相对贡献。我们的数据表明,ERK1/2和JNK在蛋白酶体抑制反应中被激活。去除蛋白酶体抑制剂(MG132)会导致ERK1/2激活增强以及JNK激活改善。用已确立的丝裂原活化蛋白激酶(MAPK)抑制剂处理会导致蛋白酶体抑制剂毒性增加,并且观察到用JNK抑制剂孵育可显著减轻蛋白酶体抑制剂毒性。随后的研究表明,抑制ERK1/2和JNK活性并不会改变蛋白酶体抑制剂给药后泛素化蛋白的总体增加。同样,ERK1/2和JNK活性似乎在蛋白酶体抑制剂给药后神经细胞中多聚核糖体的破坏过程中不起作用。这些数据共同表明,ERK1/2和JNK激活在调节蛋白酶体抑制诱导的神经化学紊乱和神经毒性方面可能发挥不同作用。